Figure 7.

The vision of applied personalized medicine in inflammatory skin diseases. Risk factors (such as FLG mutations in AD) can be identified before birth, enabling preventive measures (such as use of emollients) in early childhood. Identification of endotypes can guide targeted treatment, and a combination of predictive biomarkers and skin monitoring (aided by machine learning, including AI, integrating the information knowledge base) may help identify pre‐flares and optimal time and type of treatment.